DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Pathophysiological integration of metabolic reprogramming in breast cancer
Metabolic changes that facilitate tumor growth are one of the hallmarks of cancer. The triggers of these metabolic changes are located in the tumor parenchymal cells, where oncogenic mutations induce an imperative need to proliferate and cause tumor initiation and progression. Cancer cells undergo significant metabolic reorganization during disease progression that is tailored to their energy demands and fluctuating environmental conditions. Oxidative stress plays an essential role as a trigger under such conditions. These metabolic changes are the consequence of the interaction between tumor cells and stromal myofibroblasts. The metabolic changes in tumor cells include protein anabolism and the synthesis of cell membranes and nucleic acids, which all facilitate cell proliferation. They are linked to catabolism and autophagy in stromal myofibroblasts, causing the release of nutrients for the cells of the tumor parenchyma. Metabolic changes lead to an interstitium deficient in nutrients, such as glucose and amino acids, and acidification by lactic acid. Together with hypoxia, they produce functional changes in other cells of the tumor stroma, such as many immune subpopulations and endothelial cells, which lead to tumor growth. Thus, immune cells favor tissue growth through changes in immunosuppression. This review considers some of the metabolic changes described in breast cancer., J.P.-L.’s laboratory was partially supported by Grant SAF2017-88854R funded by MCIN/AEI/10.13039/501100011039 and by “ERDF A way of making Europe”; Grant PID2020- 118527RB-I00 funded by MCIN/AEI/10.13039/501100011039; Grant PDC2021-121735-I00 funded by MCIN/AEI/10.13039/501100011039 and by the “European Union Next Generation EU/PRTR”. The Carlos III Health Institute (PIE14/00066), the Regional Government of Castile and León (CSI234P18 and CSI144P20) and the “We can be heroes” charity. SCLl was the recipient of a Ramón y Cajal research contract from the Spanish Ministry of Economy and Competitiveness and was supported by grant RTI2018-094130-B-100 funded by MCIN/AEI/10.13039/501100011039 and by “ERDF A way of making Europe”. R.C.-C. and A.J.-N. are funded by fellowships from the Spanish Regional Government of Castile and León. N.G.-S. is a recipient of an FPU fellowship (MINECO/FEDER). M.J.P.-B. is funded by grant PID2020-118527RB-I00 funded by MCIN/AEI/10.13039/501100011039. J.C. is partially supported by grant GRS2139/A/20 (Gerencia Regional de Salud de Castilla y León) and by the Instituto de Salud Carlos III (PI18/00587 and PI21/01207), co-financed by FEDER funds, and by the “Programa de Intensificación” of the ISCIII, grant number INT20/00074.
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 SAF2017-88854-R
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-118527RB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 RTI2018-094130-B-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-118527RB-I00